<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurology</journal-id><journal-id journal-id-type="iso-abbrev">Neurology</journal-id><journal-id journal-id-type="hwp">neurology</journal-id><journal-id journal-id-type="publisher-id">neur</journal-id><journal-id journal-id-type="pmc">neurology</journal-id><journal-id journal-id-type="publisher-id">NEUROLOGY</journal-id><journal-title-group><journal-title>Neurology</journal-title></journal-title-group><issn pub-type="ppub">0028-3878</issn><issn pub-type="epub">1526-632X</issn><publisher><publisher-name>Lippincott Williams &amp; Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27511182</article-id><article-id pub-id-type="pmc">5027814</article-id><article-id pub-id-type="publisher-id">NEUROLOGY2015695569</article-id><article-id pub-id-type="doi">10.1212/WNL.0000000000003078</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>41</subject></subj-group><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The 11-year long-term follow-up study from the randomized BENEFIT CIS trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Kappos</surname><given-names>Ludwig</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>(1)Multiple Sclerosis Journal, (2)Multiple Sclerosis and Related Disorders (3)Journal of Neurology member of the Editorial Board</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>(1)Actelion, (2)Alkermes, (3)Almirall, (4)Bayer, (5)Biogen, (6)Excemed, (7)GeNeuro SA, (8)Genzyme, (9)Merck, (10)Mitsubishi Pharma, (11)Novartis, (12)Receptos, (13)Roche, (14)sanofi-aventis, (15)Santhera, (16)Teva, (17)Vianex</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>(1)the Swiss MS Society, (2)the Swiss National Research Foundation, (3)the European Union, (4)Roche Research Foundations</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>(1) Neurostatus Systems AG</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Edan</surname><given-names>Gilles</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Member of the steering committee of BENEFIT</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>For the last 5 years as regular member of the scientific board of LFB, as occasional consultant for BIOGEN , Novartis, TEVA, Sanofi</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>PHRC : programme de recherche clinique (Health ministry) : financial support for a clinical research on therapeutic strategy in MS (Natalizumab vs mitoxantrone and immunomodulator drug)2009 and a clinical research on spinal cord MRI in 2012</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>ARSEP for a research programm on imaging biomarker in MS using USPIO 2006-2009; ligue Fran?aise contre la SEP (Trial COPOUSEP published in 2015 in Lancet)</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Freedman</surname><given-names>Mark S.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Actelion, sanofi-aventis/Genzyme, Novartis, Merck Serono, Bayer, BiogenIdec, Chugai, Roche, Opexa, Teva</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>BiogenIdec, Bayer, Merck Serono, Novartis, Sanofi- Aventis/Genzyme, Teva</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>J Neurol Sci Multiple Sclerosis Multiple Sclerosis and Demyelinating Disease Int J MS Care</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>Actelion, Opexa, Novartis, Sanofi, Bayer, Merck Serono, Teva, BiogenIdec</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>Genzyme</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Montalbán</surname><given-names>Xavier</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>(1) Almirall, (2) Bayer, (3) Biogen, (4) Genzyme, (5) Merck, (6) Novartis, (7) Receptos, (8) Roche, (9) Sanofi-Genzyme, (10) Teva Pharmaceutical</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>Travel to scientific meetings: (1) Biogen, (2) Genzyme, (3) Merck, (4) Novartis, (5) Receptos, (6) Roche, (7) Sanofi-Genzyme, (8) Teva Pharmaceutical</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Member of editorial boards: (1) Multiple Sclerosis Journal, (2) Journal of Neurology, (3) The International MS Journal, (4) Revista de Neurologia, (5) Therapeutic Advances in Neurological Disorders</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>(1) Almirall, (2) Bayer, (3) Biogen, (4) Genzyme, (5) Merck, (6) Novartis, (7) Receptos, (8) Roche, (9) Sanofi-Genzyme, (10) Teva Pharmaceutical</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>(1) Vice-president, Multiple Sclerosis Foundation of Barcelona (FEM)</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Hartung</surname><given-names>Hans-Peter</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Novartis; Merck Serono; Teva; Biogen Idec; Roche; Genzyme; BayerHealthcare; Sanofi; MedImmune; GeNeuro; Opexa; Octapharma</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>Speaker Honoraria from: Biogen Idec Genzyme Teva Sanofi Aventis Merck Serono Novartis Novartis Bayer Healthcare</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>editorial board member: annals of neurology, frontiers neurology / immunology; european journal of neurology; current opinion in neurology</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Hemmer</surname><given-names>Bernhard</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Advisory board member for trials conducted by Bayer, BiogenIdec, Roche, Novartis, MerckSerono, Chugai, GSK, Genentech.</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>Sponsoring was received from Bayer, BiogenIdec, Roche, Novartis, MerckSerono for travelling and talks</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Archives of Neurologie, Experimental Neurology, MS Journal</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>(1) Anti-KIR4.1 antibody testing in MS (2) Genetic factors influencing the development of NABs</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>Gerson Lehrman Group</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Research support from Bayer, BiogenIdec, Roche, Novartis, MerckSerono, Metanomics, Chugai Pharmaceuticals.</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>Deutsche Forschungsgemeinschaft, Bundesministerium f?r Bildung und Forschung, European Community.</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>Competence Network for Multiple Sclerosis Synergy Excellence Cluster German Research Foundation Bundesministerium f?r Bildung und Forschung</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Fox</surname><given-names>Edward J.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>(1) Bayer, (2) Biogen, (3) EMD Serono, (4) Novartis, (5) Sanofi Genzyme, and (6) Teva Neuroscience</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>(1) Acorda, travel and speaker honoraria, (2) Bayer, travel and speaker honoraria (3) Biogen, travel and speaker honoraria (4) EMD Serono, travel and speaker honoraria, (4) Novartis travel and speaker honoraria, (5) Sanofi Genzyme, travel and speaker honoraria, (6) Teva Neuroscience, travel and speaker honoraria</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>Commercial: (1) Bayer, (2) Biogen, (3) EMD Serono, (4) Novartis, (5) Sanofi Genzyme, and (6) Teva Neuroscience</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>(1) Biogen, (2) EMD Serono, (3) Novartis, (4) Sanofi Genzyme, and (5) Teva Neuroscience</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>(1) Bayer (2) Biogen (3) EMD Serono, (4) Novartis, (5) Opexa (6) Genentech Roche (7) Sanofi Genzyme, and (8) Teva Neuroscience (9) TG Therapeutics</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>Assistant Clinical Professor, University of Texas Medical Branch</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>(1) National Multiple Sclerosis Society</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Barkhof</surname><given-names>Frederik</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Scientific consultant to Bayer-Schering, Sanofi- Aventis, Synthon, Novartis, Biogen-IDEC, Merck-Serono, Toshiba Medical systems, Roche, Janssen, TEVA, Genzyme</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Editorial board member for Brain, Multiple Sclerosis Journal, Neuroradiology, Radiology, Neurology</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>Consultant for Sanofi-Aventis, Synthon, Janssen, Novartis, Biogen-Idec, Roche, TEVA</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>Genzyme symposium speaker 2015 Novartis symposium speaker 2014 Biogen-sponsored symposium speaker 2014</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>EuroPOND (H2020)</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>Dutch foundation for MS Research - centre grant 2010-2014</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Schippling</surname><given-names>Sven</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>1.Bayer Healthcare 2.Biogen 3.Merck Serono 4.Novartis 5.Sanofi Genzyme 6.TEVA</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>1.Bayer Healthcare, travel compensation, speaker honoraria 2.Biogen, travel compensation, speaker honoraria 3.Merck Serono, travel compensation, speaker honoraria 4.Novartis, travel compensation, speaker honoraria 5.Sanofi Genzyme, travel compensation, speaker honoraria 6.TEVA, travel compensation, speaker honoraria</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Frontiers in Neurology, Associate Editor, 1 year</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>Therapeutic vaccination in PML using VP1 and IL7.</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>1. Sanofi Genzyme 2. Novartis</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>1. University of Zurich, Clinical Research Priority Program, Co-Director, 3 years</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>1. Betty and David Koetser Foundation for Brain Research 2. Swiss Multiple Sclerosis Society</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Schulze</surname><given-names>Andrea</given-names></name><degrees>MS</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Until 30NOV2015 I was a salaried employee of PAREXEL (i.e. the CRO responsible for the presented statistical analysis). From 01DEC2015 onwards, I was a salaried employee of Bayer (i.e. the sponsor of the presented study).</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Pleimes</surname><given-names>Dirk</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Dirk Pleimes (DP) is managing director, shareholder and a salaried employee of Myelo Pharmaceuticals GmbH. DP was a salaried employee for Bayer Pharma AG/Bayer HealthCarePharmaceuticals until September 2013.</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>Dirk Pleimes is currently a paid consultant for Bayer Pharma AG/Bayer HealthCarePharmaceuticals.</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>Dirk Pleimes owns stock in Bayer AG, the owner of Bayer Pharma AG/Bayer HealthCare Pharmaceuticals.</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Pohl</surname><given-names>Christoph</given-names></name><degrees>MD</degrees><xref ref-type="author-notes" rid="fn1">†</xref><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Sandbrink</surname><given-names>Rupert</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>(1) Bayer Healthcare AG / Bayer Pharma AG, Germany; Vice President, Head of Global Clinical Development Therapeutic Areas Neurology, Ophthalmology, Hematology and Immunology: 2007-2012; (2) Bayer Healthcare AG / Bayer Pharma AG, Germany; Vice President, Head of Experimental Medicine, Gynecologic Therapies and Common Mechanism Research, 2013- Feb 2016; (3) Current employment (since 1 March 2016): Forward Pharma A/S, Denmark: Executive Vice President Multiple Sclerosis / Neurology and Immunology</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>Stocks in Bayer as part of my employment at Bayer Healthcare</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Suarez</surname><given-names>Gustavo</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Bayer HealthCare Pharmaceuticals, Global Medical lead Neurology (past employment) Ipsen Biopharmaceuticals, Senior Medical Director (Actual)</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Wicklein</surname><given-names>Eva-Maria</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Salaried employee at Bayer Pharma AG (since 2004), Global Medical Affairs Neurology</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><collab>For the BENEFIT Study Group</collab></contrib><aff>From Neurology (L.K.), Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital Basel, Switzerland; CHU–Hopital Pontchaillou (G.E.), Rennes, France; University of Ottawa (M.S.F.), and the Ottawa Hospital Research Institute, Ottawa, Canada; Hospital Universitari Vall d'Hebron (X.M.), Ps. Vall d'Hebron, Barcelona, Spain; Department of Neurology (H.-P.H., R.S.), Medical Faculty, Heinrich-Heine Universität, Düsseldorf; Technische Universität München (B.H.), Munich, Germany; Central Texas Neurology Consultants (E.J.F.), Round Rock, TX; VU University Medical Center (F.B.), Amsterdam, the Netherlands; Neuroimmunology and Multiple Sclerosis Research (S.S.), Department of Neurology, University Hospital Zurich and University of Zurich, Switzerland; Bayer Pharma AG (A.S., C.P., E.-M.W.), Berlin; Myelo Therapeutics GmbH (D.P.), Berlin; University Hospital of Bonn (C.P.), Germany; and Bayer HealthCare Pharmaceuticals (G.S.), Whippany, NJ.</aff></contrib-group><contrib-group><contrib contrib-type="collab"><collab>BENEFIT Study Group</collab></contrib><contrib contrib-type="collab"><name><surname>Strasser-Fuchs</surname><given-names>S</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Berger</surname><given-names>T</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Vass</surname><given-names>K</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Sindic</surname><given-names>C</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Dubois</surname><given-names>B</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Dive</surname><given-names>D</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Delvaux</surname><given-names>V</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Debruyne</surname><given-names>J</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Metz</surname><given-names>L</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Rice</surname><given-names>G</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Kremenchutzky</surname><given-names>M</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Duquette</surname><given-names>P</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Lapierre</surname><given-names>Y</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Freedman</surname><given-names>M</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Traboulsee</surname><given-names>A</given-names></name></contrib><contrib contrib-type="collab"><name><surname>O'Connor</surname><given-names>P</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Stourac</surname><given-names>P</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Talab</surname><given-names>R</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Valis</surname><given-names>M</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Zapletalova</surname><given-names>O</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Kovarova</surname><given-names>I</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Medova</surname><given-names>E</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Fiedler</surname><given-names>J</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Frederiksen</surname><given-names>J</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Brochet</surname><given-names>B</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Moreau</surname><given-names>T</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Vermersch</surname><given-names>P</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Pelletier</surname><given-names>J</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Edan</surname><given-names>G</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Clanet</surname><given-names>M</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>David</surname><given-names>B</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Clavelou</surname><given-names>P</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Lebrun-Frenay</surname><given-names>C</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Gout</surname><given-names>O</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Kallela</surname><given-names>M</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Pirttila</surname><given-names>T</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Ruutiainen</surname><given-names>J</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Erälinna</surname><given-names>JP</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Koivisto</surname><given-names>K</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Reunanen</surname><given-names>M</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Keskinarkus</surname><given-names>I</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Elovaara</surname><given-names>I</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Villringer</surname><given-names>A</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Altenkirch</surname><given-names>H</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Bauer</surname><given-names>L</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Ghazi</surname><given-names>M</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Pohl</surname><given-names>C</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Wessel</surname><given-names>K</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Hartung</surname><given-names>H-P</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Steinke</surname><given-names>W</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Kieseier</surname><given-names>B</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Kolmel</surname><given-names>H</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Oschmann</surname><given-names>P</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Berghoff</surname><given-names>M</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Diem</surname><given-names>R</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Kitze</surname><given-names>B</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Dressel</surname><given-names>A</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Hoffmann</surname><given-names>F</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Baum</surname><given-names>K</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Jung</surname><given-names>S</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Petereit</surname><given-names>H Felicitas</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Reske</surname><given-names>D</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Sailer</surname><given-names>M</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Kohler</surname><given-names>J</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Tackenberg</surname><given-names>B</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Klotz</surname><given-names>L</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Hohlfeld</surname><given-names>R</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Kuempfel</surname><given-names>T</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Henn</surname><given-names>K-H</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Steinbrecher</surname><given-names>A</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Angstwurm</surname><given-names>K</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Tumani</surname><given-names>H</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Gold</surname><given-names>R</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Rieckmann</surname><given-names>P</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Kleinschnitz</surname><given-names>C</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Komoly</surname><given-names>R</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Gacs</surname><given-names>G</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Jakab</surname><given-names>G</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Panczel</surname><given-names>G</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Csepany</surname><given-names>T</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Csiba</surname><given-names>L</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Vecsei</surname><given-names>L</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Miller</surname><given-names>A</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Karussis</surname><given-names>D</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Chapman</surname><given-names>J</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Ghezzi</surname><given-names>A</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Comi</surname><given-names>G</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Martinelli</surname><given-names>V</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Gallo</surname><given-names>P</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Cosi</surname><given-names>V</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Bergamaschi</surname><given-names>R</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Durelli</surname><given-names>L</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Cavalla</surname><given-names>P</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Polman</surname><given-names>CH</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Barkhof</surname><given-names>F</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Uitdehaag</surname><given-names>B</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Anten</surname><given-names>B</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Hupperts</surname><given-names>R</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Visser</surname><given-names>L</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Myhr</surname><given-names>K-M</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Szczudlik</surname><given-names>A</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Selmaj</surname><given-names>K</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Stelmasiak</surname><given-names>Z</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Barosik-Psujek</surname><given-names>H</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Podemski</surname><given-names>R</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Maciejek</surname><given-names>Z</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Wawrzyniak</surname><given-names>S</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Cunha</surname><given-names>L</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Sega-Jazbec</surname><given-names>S</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Montalbán</surname><given-names>X</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Arbizu</surname><given-names>T</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Saiz Hinarejos</surname><given-names>A</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Barcena</surname><given-names>J</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Yélamos</surname><given-names>S Martínez</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Arroyo</surname><given-names>R</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Fernandez</surname><given-names>O</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Ayuso</surname><given-names>G Izquierdo</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Casanova i Estruch</surname><given-names>B</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Lycke</surname><given-names>J</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Kappos</surname><given-names>L</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>de Vera</surname><given-names>A</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Wu</surname><given-names>S</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Radue</surname><given-names>E-W</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Kuhle</surname><given-names>J</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Mattle</surname><given-names>H</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Beer</surname><given-names>K</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Coleman</surname><given-names>R</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Miller</surname><given-names>DH</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Chataway</surname><given-names>J</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>O'Riordan</surname><given-names>J</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Howell</surname><given-names>S</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Edan</surname><given-names>G</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Freedman</surname><given-names>M</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Hartung</surname><given-names>H-P</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Kappos</surname><given-names>L</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Miller</surname><given-names>DH</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Montalbán</surname><given-names>X</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Polman</surname><given-names>CH</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Bauer</surname><given-names>L</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Ghazi</surname><given-names>M</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Pohl</surname><given-names>C</given-names></name><degrees>MD.</degrees></contrib><contrib contrib-type="collab"><name><surname>Polman</surname><given-names>CH</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Barkhof</surname><given-names>F</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Uitdehaag</surname><given-names>B</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Kappos</surname><given-names>L</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>de Vera</surname><given-names>A</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Wu</surname><given-names>S</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Barkhof</surname><given-names>F</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Radue</surname><given-names>E-W</given-names></name><degrees>MD.</degrees></contrib><contrib contrib-type="collab"><name><surname>McFarland</surname><given-names>HF</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Kesselring</surname><given-names>J</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Petkau</surname><given-names>AJ</given-names></name><degrees>PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Toyka</surname><given-names>KV</given-names></name><degrees>MD.</degrees></contrib></contrib-group><author-notes><corresp>Correspondence to Prof. Kappos: <email>Ludwig.Kappos@usb.ch</email></corresp><fn fn-type="other" id="fn1"><label>†</label><p>Deceased.</p></fn><fn fn-type="other"><p>BENEFIT Study Group coinvestigators are listed at <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000003078">Neurology.org</ext-link>.</p></fn><fn fn-type="financial-disclosure"><p>Go to <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000003078">Neurology.org</ext-link> for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was paid by Bayer Pharma AG/Bayer HealthCare Pharmaceuticals.</p></fn></author-notes><pub-date pub-type="ppub"><day>06</day><month>9</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>06</day><month>9</month><year>2016</year></pub-date><volume>87</volume><issue>10</issue><fpage>978</fpage><lpage>987</lpage><history><date date-type="received"><day>28</day><month>9</month><year>2015</year></date><date date-type="accepted"><day>14</day><month>4</month><year>2016</year></date></history><permissions><copyright-statement>© 2016 American Academy of Neurology</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>American Academy of Neurology</copyright-holder><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="NEUROLOGY2015695569.pdf"></self-uri><abstract><sec><title><offsets xml_i="71118" xml_f="71128" txt_i="11" txt_f="21">Objective:</offsets></title><p><offsets xml_i="71139" xml_f="71279" txt_i="22" txt_f="162">To assess outcomes for patients treated with interferon beta-1b immediately after clinically isolated syndrome (CIS) or after a short delay.</offsets></p></sec><sec><title><offsets xml_i="71301" xml_f="71309" txt_i="164" txt_f="172">Methods:</offsets></title><p><offsets xml_i="71320" xml_f="71726" txt_i="173" txt_f="579">Participants in BENEFIT (Betaferon/Betaseron in Newly Emerging MS for Initial Treatment) were randomly assigned to receive interferon beta-1b (early treatment) or placebo (delayed treatment). After conversion to clinically definite multiple sclerosis (CDMS) or 2 years, patients on placebo could switch to interferon beta-1b or another treatment. Eleven years after randomization, patients were reassessed.</offsets></p></sec><sec><title><offsets xml_i="71748" xml_f="71756" txt_i="581" txt_f="589">Results:</offsets></title><p><offsets xml_i="71767" xml_f="72049" txt_i="590" txt_f="872">Two hundred seventy-eight (59.4%) of the original 468 patients (71.3% of those eligible at participating sites) were enrolled (early: 167 [57.2%]; delayed: 111 [63.1%]). After 11 years, risk of CDMS remained lower in the early-treatment arm compared with the delayed-treatment arm (</offsets><italic><offsets xml_i="72057" xml_f="72058" txt_i="872" txt_f="873">p</offsets></italic><offsets xml_i="72067" xml_f="72182" txt_i="873" txt_f="988"> = 0.0012), with longer time to first relapse (median [Q1, Q3] days: 1,888 [540, not reached] vs 931 [253, 3,296]; </offsets><italic><offsets xml_i="72190" xml_f="72191" txt_i="988" txt_f="989">p</offsets></italic><offsets xml_i="72200" xml_f="72268" txt_i="989" txt_f="1057"> = 0.0005) and lower overall annualized relapse rate (0.21 vs 0.26; </offsets><italic><offsets xml_i="72276" xml_f="72277" txt_i="1057" txt_f="1058">p</offsets></italic><offsets xml_i="72286" xml_f="72645" txt_i="1058" txt_f="1417"> = 0.0018). Only 25 patients (5.9%, overall; early, 4.5%; delayed, 8.3%) converted to secondary progressive multiple sclerosis. Expanded Disability Status Scale scores remained low and stable, with no difference between treatment arms (median [Q1, Q3]: 2.0 [1.0, 3.0]). The early-treatment group had better Paced Auditory Serial Addition Task–3 total scores (</offsets><italic><offsets xml_i="72653" xml_f="72654" txt_i="1417" txt_f="1418">p</offsets></italic><offsets xml_i="72663" xml_f="72814" txt_i="1418" txt_f="1569"> = 0.0070). Employment rates remained high, and health resource utilization tended to be low in both groups. MRI metrics did not differ between groups.</offsets></p></sec><sec><title><offsets xml_i="72836" xml_f="72848" txt_i="1571" txt_f="1583">Conclusions:</offsets></title><p><offsets xml_i="72859" xml_f="73085" txt_i="1584" txt_f="1810">Although the delay in treatment was relatively short, several clinical outcomes favored earlier treatment. Along with low rates of disability and disease progression in both groups, this supports the value of treatment at CIS.</offsets></p></sec><sec><title><offsets xml_i="73107" xml_f="73137" txt_i="1812" txt_f="1842">ClinicalTrials.gov identifier:</offsets></title><p><offsets xml_i="73148" xml_f="73160" txt_i="1843" txt_f="1855">NCT01795872.</offsets></p></sec><sec><title><offsets xml_i="73182" xml_f="73209" txt_i="1857" txt_f="1884">Classification of evidence:</offsets></title><p><offsets xml_i="73220" xml_f="73343" txt_i="1885" txt_f="2008">This study provides Class IV evidence that early compared to delayed treatment prolongs time to CDMS in CIS after 11 years.</offsets></p></sec></abstract><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>special-property</meta-name><meta-value>triangle</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p><offsets xml_i="73624" xml_f="73842" txt_i="2017" txt_f="2235">Patients with multiple sclerosis (MS), the most common chronic demyelinating disorder of the CNS, often present with an acute or subacute episode of neurologic dysfunction known as a clinically isolated syndrome (CIS).</offsets><sup><xref rid="R1" ref-type="bibr"><offsets xml_i="73878" xml_f="73879" txt_i="2235" txt_f="2236">1</offsets></xref><offsets xml_i="73886" xml_f="73887" txt_i="2236" txt_f="2237">,</offsets><xref rid="R2" ref-type="bibr"><offsets xml_i="73918" xml_f="73919" txt_i="2237" txt_f="2238">2</offsets></xref></sup><offsets xml_i="73932" xml_f="74079" txt_i="2238" txt_f="2385"> Eventually, most of these patients (up to 85%) will be diagnosed with MS once evidence for dissemination of lesions in space and time accumulates.</offsets><sup><xref rid="R2" ref-type="bibr"><offsets xml_i="74115" xml_f="74116" txt_i="2385" txt_f="2386">2</offsets></xref><offsets xml_i="74123" xml_f="74124" txt_i="2386" txt_f="2387">,</offsets><xref rid="R3" ref-type="bibr"><offsets xml_i="74155" xml_f="74156" txt_i="2387" txt_f="2388">3</offsets></xref></sup></p><p><offsets xml_i="74176" xml_f="74320" txt_i="2389" txt_f="2533">Several controlled studies have shown that conversion to MS can be delayed by starting treatment with disease-modifying therapies (DMTs) at CIS.</offsets><sup><xref rid="R4" ref-type="bibr"><offsets xml_i="74356" xml_f="74357" txt_i="2533" txt_f="2534">4</offsets></xref><xref ref-type="bibr" rid="R5"><offsets xml_i="74395" xml_f="74396" txt_i="2534" txt_f="2535">–</offsets></xref><xref rid="R11" ref-type="bibr"><offsets xml_i="74435" xml_f="74437" txt_i="2535" txt_f="2537">11</offsets></xref></sup><offsets xml_i="74450" xml_f="74708" txt_i="2537" txt_f="2795"> However, data about the effects of starting treatment this early on the long-term disease course, including potential improvements relative to delayed treatment on measures of confirmed disability progression, participation, and quality of life, are scarce.</offsets></p><p><offsets xml_i="74715" xml_f="75127" txt_i="2796" txt_f="3208">The 5-year Betaferon/Betaseron in Newly Emerging MS for Initial Treatment (BENEFIT) trial and its 8-year extension have shown improved outcomes in patients who initiated treatment with interferon beta-1b (Betaferon/Betaseron; Bayer HealthCare Pharmaceuticals, Whippany, NJ) immediately after CIS, relative to patients who had started treatment after their second clinical event or 2 years post-CIS at the latest.</offsets><sup><xref rid="R6" ref-type="bibr"><offsets xml_i="75163" xml_f="75164" txt_i="3208" txt_f="3209">6</offsets></xref><offsets xml_i="75171" xml_f="75172" txt_i="3209" txt_f="3210">,</offsets><xref rid="R10" ref-type="bibr"><offsets xml_i="75204" xml_f="75206" txt_i="3210" txt_f="3212">10</offsets></xref></sup><offsets xml_i="75219" xml_f="75369" txt_i="3212" txt_f="3362"> Specifically, we have shown delays in conversion to CDMS and reductions in the annualized relapse rate (ARR) 2, 3, 5, and 8 years after randomization</offsets><sup><xref rid="R6" ref-type="bibr"><offsets xml_i="75405" xml_f="75406" txt_i="3362" txt_f="3363">6</offsets></xref><offsets xml_i="75413" xml_f="75414" txt_i="3363" txt_f="3364">,</offsets><xref rid="R8" ref-type="bibr"><offsets xml_i="75445" xml_f="75446" txt_i="3364" txt_f="3365">8</offsets></xref><xref ref-type="bibr" rid="R9"><offsets xml_i="75484" xml_f="75485" txt_i="3365" txt_f="3366">–</offsets></xref><xref rid="R10" ref-type="bibr"><offsets xml_i="75524" xml_f="75526" txt_i="3366" txt_f="3368">10</offsets></xref></sup><offsets xml_i="75539" xml_f="75714" txt_i="3368" txt_f="3543"> but only a small change in mean Expanded Disability Status Scale (EDSS) score in both treatment groups up to the 8-year analysis, indicating a relatively mild disease course.</offsets><sup><xref rid="R6" ref-type="bibr"><offsets xml_i="75750" xml_f="75751" txt_i="3543" txt_f="3544">6</offsets></xref></sup><offsets xml_i="75764" xml_f="75934" txt_i="3544" txt_f="3714"> The objective of the present study was to examine the longer-term effects of treatment with interferon beta-1b on the disease course at 11 years after occurrence of CIS.</offsets></p><sec sec-type="methods" id="s1"><title><offsets xml_i="75977" xml_f="75984" txt_i="3715" txt_f="3722">METHODS</offsets></title><sec id="s1-1"><title><offsets xml_i="76014" xml_f="76032" txt_i="3723" txt_f="3741">Patient selection.</offsets></title><p><offsets xml_i="76043" xml_f="76418" txt_i="3742" txt_f="4117">The phase 3 BENEFIT trial consisted of a prospective, 2-year, international, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of interferon beta-1b 250 μg administered subcutaneously every other day with a preplanned open-label interferon beta-1b treatment follow-up phase, blinded to the initial treatment allocation and lasting up to 5 years.</offsets><sup><xref rid="R10" ref-type="bibr"><offsets xml_i="76455" xml_f="76457" txt_i="4117" txt_f="4119">10</offsets></xref></sup><offsets xml_i="76470" xml_f="76667" txt_i="4119" txt_f="4316"> All patients had experienced a CIS suggestive of MS and had ≥2 clinically silent MRI lesions. Enrollment was completed at centers in Europe, Canada, and Israel between February 2002 and June 2003.</offsets><sup><xref rid="R10" ref-type="bibr"><offsets xml_i="76704" xml_f="76706" txt_i="4316" txt_f="4318">10</offsets></xref></sup><offsets xml_i="76719" xml_f="76854" txt_i="4318" txt_f="4453"> The 5-year core and follow-up study was followed by an open-label observational extension study with a maximum follow-up of 8.7 years.</offsets><sup><xref rid="R6" ref-type="bibr"><offsets xml_i="76890" xml_f="76891" txt_i="4453" txt_f="4454">6</offsets></xref></sup><offsets xml_i="76904" xml_f="77085" txt_i="4454" txt_f="4635"> Following the extension study, the investigators decided to conduct a prospective, comprehensive, 11-year, cross-sectional reassessment (BENEFIT 11 Study), which is presented here.</offsets></p></sec><sec id="s1-2"><title><offsets xml_i="77117" xml_f="77143" txt_i="4637" txt_f="4663">Randomization and masking.</offsets></title><p><offsets xml_i="77154" xml_f="77540" txt_i="4664" txt_f="5050">In the core study, patients were randomized (5:3) by means of a central interactive voice response system within 60 days of CIS to receive either interferon beta-1b 250 μg (early treatment) or placebo (delayed treatment) subcutaneously every other day. After 2 years or conversion to CDMS, all patients could have treatment with interferon beta-1b but could also take another or no DMT.</offsets></p></sec><sec id="s1-3"><title><offsets xml_i="77572" xml_f="77584" txt_i="5052" txt_f="5064">Assessments.</offsets></title><p><offsets xml_i="77595" xml_f="77921" txt_i="5065" txt_f="5391">Eleven years after randomization, all patients from participating study centers who were randomized and treated at least once in the placebo-controlled phase were eligible to enter the 11-year follow-up and were approached to participate in a comprehensive reassessment. The battery of assessments included (see figure e-1 at </offsets><ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000003078"><offsets xml_i="78025" xml_f="78038" txt_i="5391" txt_f="5404">Neurology.org</offsets></ext-link><offsets xml_i="78049" xml_f="78142" txt_i="5404" txt_f="5497"> for full list): neurologic history and examination (relapses, current disease course), EDSS,</offsets><sup><xref rid="R12" ref-type="bibr"><offsets xml_i="78179" xml_f="78181" txt_i="5497" txt_f="5499">12</offsets></xref></sup><offsets xml_i="78194" xml_f="78235" txt_i="5499" txt_f="5540"> Multiple Sclerosis Functional Composite,</offsets><sup><xref rid="R13" ref-type="bibr"><offsets xml_i="78272" xml_f="78274" txt_i="5540" txt_f="5542">13</offsets></xref></sup><offsets xml_i="78287" xml_f="78384" txt_i="5542" txt_f="5639"> employment status and resource use, health-related quality of life (EuroQoL–5 Dimension [EQ-5D],</offsets><sup><xref rid="R14" ref-type="bibr"><offsets xml_i="78421" xml_f="78423" txt_i="5639" txt_f="5641">14</offsets></xref></sup><offsets xml_i="78436" xml_f="78489" txt_i="5641" txt_f="5694"> Functional Assessment of Multiple Sclerosis [FAMS]),</offsets><sup><xref rid="R15" ref-type="bibr"><offsets xml_i="78526" xml_f="78528" txt_i="5694" txt_f="5696">15</offsets></xref></sup><offsets xml_i="78541" xml_f="78614" txt_i="5696" txt_f="5769"> depressive symptoms (Center for Epidemiologic Studies Depression Scale),</offsets><sup><xref rid="R16" ref-type="bibr"><offsets xml_i="78651" xml_f="78653" txt_i="5769" txt_f="5771">16</offsets></xref></sup><offsets xml_i="78666" xml_f="78725" txt_i="5771" txt_f="5830"> fatigue (Fatigue Scale for Motor and Cognitive Functions),</offsets><sup><xref rid="R17" ref-type="bibr"><offsets xml_i="78762" xml_f="78764" txt_i="5830" txt_f="5832">17</offsets></xref><offsets xml_i="78771" xml_f="78772" txt_i="5832" txt_f="5833">,</offsets><xref rid="R18" ref-type="bibr"><offsets xml_i="78804" xml_f="78806" txt_i="5833" txt_f="5835">18</offsets></xref></sup><offsets xml_i="78819" xml_f="78938" txt_i="5835" txt_f="5954"> MS medication history, cognition (Paced Auditory Serial Addition Task [PASAT]-3, Symbol Digit Modalities Test [SDMT]),</offsets><sup><xref rid="R19" ref-type="bibr"><offsets xml_i="78975" xml_f="78977" txt_i="5954" txt_f="5956">19</offsets></xref><offsets xml_i="78984" xml_f="78985" txt_i="5956" txt_f="5957">,</offsets><xref rid="R20" ref-type="bibr"><offsets xml_i="79017" xml_f="79019" txt_i="5957" txt_f="5959">20</offsets></xref></sup><offsets xml_i="79032" xml_f="79292" txt_i="5959" txt_f="6219"> and MRI. Investigators conducted patient assessments at their respective centers but, to include sicker patients who were unable to attend a center in person, a structured interview via phone that included a validated instrument for the assessment of the EDSS</offsets><sup><xref rid="R21" ref-type="bibr"><offsets xml_i="79329" xml_f="79331" txt_i="6219" txt_f="6221">21</offsets></xref><offsets xml_i="79338" xml_f="79339" txt_i="6221" txt_f="6222">,</offsets><xref rid="R22" ref-type="bibr"><offsets xml_i="79371" xml_f="79373" txt_i="6222" txt_f="6224">22</offsets></xref></sup><offsets xml_i="79386" xml_f="79417" txt_i="6224" txt_f="6255"> was offered as an alternative.</offsets></p><p><offsets xml_i="79424" xml_f="79486" txt_i="6256" txt_f="6318">CDMS was defined according to slightly modified Poser criteria</offsets><sup><xref rid="R23" ref-type="bibr"><offsets xml_i="79523" xml_f="79525" txt_i="6318" txt_f="6320">23</offsets></xref></sup><offsets xml_i="79538" xml_f="80005" txt_i="6320" txt_f="6787"> as (1) a relapse with clinical evidence of ≥1 CNS lesion, and if the first presentation was monofocal, a lesion distinct from the one responsible for the CIS presentation, or (2) sustained progression by ≥1.5 points on the EDSS reaching a total EDSS score of ≥2.5 and confirmed at a consecutive visit 3 months later. Such EDSS progression must have been based on objective clinical evidence of ≥1 neurologic abnormality other than vegetative or cerebral dysfunction.</offsets></p><p><offsets xml_i="80012" xml_f="80547" txt_i="6788" txt_f="7323">EDSS progression (unrelated to the CDMS definition) was defined as an increase of ≥1 point compared with the initial EDSS score (the lower of the 2 scores obtained during screening and baseline) or an increase of ≥1.5 points if the initial score was 0. A confirmed EDSS progression was defined as a progression confirmed at a scheduled study visit ≥140 days later. A sustained EDSS progression was defined as a progression that had been confirmed in the course of BENEFIT or BENEFIT follow-up and was sustained up to the 11-year visit.</offsets></p><p><offsets xml_i="80554" xml_f="80846" txt_i="7324" txt_f="7616">Investigators collected MRI data at study sites according to a standardized MRI protocol. Scans were analyzed at a central reading site (VU University Medical Center, Amsterdam, the Netherlands). Trained readers manually identified and quantified lesions using a local thresholding technique.</offsets></p></sec><sec id="s1-4"><title><offsets xml_i="80878" xml_f="80901" txt_i="7618" txt_f="7641">Statistical procedures.</offsets></title><p><offsets xml_i="80912" xml_f="82466" txt_i="7642" txt_f="9196">Statistical modeling was used to estimate treatment effects and explore the relationships of target variables to treatment. The study was exploratory in nature, with the primary objective to describe disease course, particularly time to conversion to CDMS (Class III evidence) and/or secondary progressive MS (SPMS), relapse activity, change in disability, cognitive function, resource use, and working status (Class IV evidence) at year 11. Secondary objectives included assessment of MRI, treatment history, quality of life, depression, and DMT choices. Variables of primary and secondary interest were assessed using proportional hazards regression for time-to-event outcomes and generalized linear regression models, with steroid use during first event (yes or no), multifocal or monofocal onset of disease, and number of T2 lesions at screening (2–4, 5–8, or ≥9) included as the standard set of covariates. An extended set of covariates that included number of gadolinium-enhancing (Gd+) lesions at screening, age, and sex in addition to the standard covariates was used for analysis of time to CDMS, time to first relapse, and ARR. Other variables were analyzed using nonparametric methods. A negative binomial regression model for T1 lesions adjusting for T2 lesions at screening and initial treatment as independent variables was fitted. Changes in imaging hardware and software precluded comparisons of MRI-related outcomes over time. Therefore, only cross-sectional MRI comparisons at year 11 between early and delayed treatment were performed.</offsets></p></sec><sec id="s1-5"><title><offsets xml_i="82498" xml_f="82525" txt_i="9198" txt_f="9225">Classification of evidence.</offsets></title><p><offsets xml_i="82536" xml_f="82715" txt_i="9226" txt_f="9405">The primary research question of the study was to assess the effect of treatment with interferon beta-1b at CIS or after a short delay on clinical and MRI outcomes after 11 years.</offsets></p></sec><sec id="s1-6"><title><offsets xml_i="82747" xml_f="82812" txt_i="9407" txt_f="9472">Standard protocol approvals, registrations, and patient consents.</offsets></title><p><offsets xml_i="82823" xml_f="83035" txt_i="9473" txt_f="9685">The institutional review boards of participating institutions approved the protocol for the study. Patients provided informed consent at enrollment into each phase of the trial. The BENEFIT 11 trial is listed on </offsets><ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov"><offsets xml_i="83104" xml_f="83122" txt_i="9685" txt_f="9703">clinicaltrials.gov</offsets></ext-link><offsets xml_i="83133" xml_f="83152" txt_i="9703" txt_f="9722"> under NCT01795872.</offsets></p></sec></sec><sec sec-type="results" id="s2"><title><offsets xml_i="83207" xml_f="83214" txt_i="9725" txt_f="9732">RESULTS</offsets></title><sec id="s2-1"><title><offsets xml_i="83244" xml_f="83264" txt_i="9733" txt_f="9753">Patient disposition.</offsets></title><p><offsets xml_i="83275" xml_f="83575" txt_i="9754" txt_f="10054">Of the 468 patients originally randomized in BENEFIT, 278 (59.4%) enrolled in BENEFIT 11 (167 [57.2%] from the early-treatment arm and 111 [63.1%] from the delayed-treatment arm) between September 2013 and April 2014 in the 66 of 97 sites in 19 countries that participated in this 11-year follow-up (</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="83605" xml_f="83613" txt_i="10054" txt_f="10062">figure 1</offsets></xref><offsets xml_i="83620" xml_f="83862" txt_i="10062" txt_f="10304">). A total of 71.3% of the patients originally randomized and treated in these participating sites were enrolled. Two hundred thirty-seven patients (85.3%) had in-person assessments at study centers; 41 patients (14.7%) had phone assessments.</offsets></p><fig id="F1" orientation="portrait" position="float"><label><offsets xml_i="83926" xml_f="83934" txt_i="10305" txt_f="10313">Figure 1</offsets></label><caption><title><offsets xml_i="83958" xml_f="84000" txt_i="10313" txt_f="10355">Study profile for the entire BENEFIT Study</offsets></title><p><sup><offsets xml_i="84016" xml_f="84017" txt_i="10356" txt_f="10357">a</offsets></sup><offsets xml_i="84023" xml_f="84111" txt_i="10357" txt_f="10445">Includes one patient randomized to receive interferon beta-1b but treated with placebo. </offsets><sup><offsets xml_i="84116" xml_f="84117" txt_i="10445" txt_f="10446">b</offsets></sup><offsets xml_i="84123" xml_f="84211" txt_i="10446" txt_f="10534">Includes one patient randomized to receive placebo but treated with interferon beta-1b. </offsets><sup><offsets xml_i="84216" xml_f="84217" txt_i="10534" txt_f="10535">c</offsets></sup><offsets xml_i="84223" xml_f="84339" txt_i="10535" txt_f="10651">Includes one patient entered into the BENEFIT follow-up study after premature discontinuation of the BENEFIT Study. </offsets><sup><offsets xml_i="84344" xml_f="84345" txt_i="10651" txt_f="10652">d</offsets></sup><offsets xml_i="84351" xml_f="84452" txt_i="10652" txt_f="10753">Four lost to follow-up, 2 missing data, 1 noncompliance, 1 treatment failure, 2 refused final visit. </offsets><sup><offsets xml_i="84457" xml_f="84458" txt_i="10753" txt_f="10754">e</offsets></sup><offsets xml_i="84464" xml_f="84571" txt_i="10754" txt_f="10861">Three lost to follow-up, 1 relocated away from site, 1 pregnancy, 1 unable to attend visit because of job. </offsets><sup><offsets xml_i="84576" xml_f="84577" txt_i="10861" txt_f="10862">f</offsets></sup><offsets xml_i="84583" xml_f="84933" txt_i="10862" txt_f="11212">To be eligible for the 11-year follow-up, patients only needed to be randomized and treated in the original BENEFIT Study (i.e., they did not need to be included in the previous BENEFIT analyses). BENEFIT = Betaferon/Betaseron in Newly Emerging MS for Initial Treatment; CDMS = clinically definite multiple sclerosis; DMT = disease-modifying therapy.</offsets></p></caption><graphic xlink:href="NEUROLOGY2015695569FF1"></graphic></fig><p><offsets xml_i="85011" xml_f="85187" txt_i="11213" txt_f="11389">Baseline characteristics and outcomes of the original cohort vs BENEFIT 11 participants at their last study visits before the 11-year follow-up were generally well comparable (</offsets><xref ref-type="table" rid="T1"><offsets xml_i="85219" xml_f="85226" txt_i="11389" txt_f="11396">table 1</offsets></xref><offsets xml_i="85233" xml_f="85843" txt_i="11396" txt_f="12006">) with the exception of a somewhat higher number converting to CDMS in the 11-year follow-up group. Patients in the early- and delayed-treatment arms of the 11-year follow-up also had similar baseline characteristics. The mean (SD) delay until starting interferon beta-1b treatment was 1.5 (0.73) years in the delayed-treatment group. One hundred seventy-one (61.5%) of the 278 patients enrolled in BENEFIT 11 were on a DMT at the time of assessment; 86 (30.9%) were on interferon beta-1b. Mean (SD) time on interferon beta-1b was 1,523.2 (861.4) days over the 11 years, excluding the BENEFIT Study medication.</offsets></p><table-wrap id="T1" orientation="portrait" position="float"><label><offsets xml_i="85914" xml_f="85921" txt_i="12007" txt_f="12014">Table 1</offsets></label><caption><p><offsets xml_i="85941" xml_f="86170" txt_i="12014" txt_f="12243">Patient characteristics at baseline in the originally randomized BENEFIT population and in those participating in the BENEFIT 11 Study and patient characteristics at last follow-up in patients who did and did not enter BENEFIT 11</offsets></p></caption><graphic xlink:href="NEUROLOGY2015695569TT1"></graphic></table-wrap></sec><sec id="s2-2"><title><offsets xml_i="86280" xml_f="86298" txt_i="12245" txt_f="12263">Clinical outcomes.</offsets></title><p><offsets xml_i="86309" xml_f="86533" txt_i="12264" txt_f="12488">After 11 years, the risk of conversion to CDMS was still reduced by 33.0% for patients in the early-treatment arm relative to those in the delayed-treatment arm (hazard ratio 0.670; 95% confidence interval [CI] 0.526–0.854, </offsets><italic><offsets xml_i="86541" xml_f="86542" txt_i="12488" txt_f="12489">p</offsets></italic><offsets xml_i="86551" xml_f="86562" txt_i="12489" txt_f="12500"> = 0.0012; </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="86592" xml_f="86601" txt_i="12500" txt_f="12509">figure 2A</offsets></xref><offsets xml_i="86608" xml_f="86948" txt_i="12509" txt_f="12849">). One hundred sixty-two patients (66.6% of total early-treatment group; Kaplan-Meier [KM] estimate) in the early-treatment group and 118 (75.0% of total delayed-treatment group [KM estimate]) in the delayed-treatment group had converted to CDMS at any time until BENEFIT 11. Time to CDMS was shorter in the delayed-treatment arm (log rank </offsets><italic><offsets xml_i="86956" xml_f="86957" txt_i="12849" txt_f="12850">p</offsets></italic><offsets xml_i="86966" xml_f="87052" txt_i="12850" txt_f="12936"> = 0.0034) as well as time to first relapse (hazard ratio 0.655 [95% CI 0.517–0.830], </offsets><italic><offsets xml_i="87060" xml_f="87061" txt_i="12936" txt_f="12937">p</offsets></italic><offsets xml_i="87070" xml_f="87414" txt_i="12937" txt_f="13281"> = 0.0005). Risk of a first relapse was reduced by 34.5% in the early-treatment compared with the delayed-treatment group. The overall ARR over the 11-year study period was lower in the early-treatment group than in the delayed-treatment group, resulting in a 19.1% reduction in risk of relapses (risk ratio [RR] 0.8094 [95% CI 0.7090–0.9242], </offsets><italic><offsets xml_i="87422" xml_f="87423" txt_i="13281" txt_f="13282">p</offsets></italic><offsets xml_i="87432" xml_f="87443" txt_i="13282" txt_f="13293"> = 0.0018; </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="87473" xml_f="87482" txt_i="13293" txt_f="13302">figure 2B</offsets></xref><offsets xml_i="87489" xml_f="87506" txt_i="13302" txt_f="13319">). Inspection of </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="87536" xml_f="87545" txt_i="13319" txt_f="13328">figure 2B</offsets></xref><offsets xml_i="87552" xml_f="87794" txt_i="13328" txt_f="13570"> revealed that the ARR by study year was not only different during the core study but also remained lower in all but 2 of the follow-up years, although after the second year, both groups were similarly exposed to interferon beta-1b treatment.</offsets></p><fig id="F2" orientation="portrait" position="float"><label><offsets xml_i="87858" xml_f="87866" txt_i="13571" txt_f="13579">Figure 2</offsets></label><caption><title><offsets xml_i="87890" xml_f="87998" txt_i="13579" txt_f="13687">Kaplan-Meier estimates of probability of CDMS (A), ARR (B), and EDSS scores (C) in the BENEFIT 11 population</offsets></title><p><sup><offsets xml_i="88014" xml_f="88015" txt_i="13688" txt_f="13689">a</offsets></sup><offsets xml_i="88021" xml_f="88483" txt_i="13689" txt_f="14151">One patient in the early-treatment arm was excluded from this analysis because diagnosis of CDMS was unclear. Risk of conversion to CDMS was significantly lower for the early-treatment group compared with the delayed-treatment group. Overall ARR was significantly lower in the early-treatment group compared with the delayed-treatment group. As expected, EDSS scores increased from baseline to year 11, but they tended to remain relatively low for both groups. *</offsets><italic><offsets xml_i="88491" xml_f="88492" txt_i="14151" txt_f="14152">p</offsets></italic><offsets xml_i="88501" xml_f="88515" txt_i="14152" txt_f="14163"> &lt; 0.05; **</offsets><italic><offsets xml_i="88523" xml_f="88524" txt_i="14163" txt_f="14164">p</offsets></italic><offsets xml_i="88533" xml_f="88799" txt_i="14164" txt_f="14427"> &lt; 0.01. ARR = annualized relapse rate; BENEFIT = Betaferon/Betaseron in Newly Emerging MS for Initial Treatment; CDMS = clinically definite multiple sclerosis; CI = confidence interval; EDSS = Expanded Disability Status Scale; HR = hazard ratio; RR = risk ratio.</offsets></p></caption><graphic xlink:href="NEUROLOGY2015695569FF2"></graphic></fig><p><offsets xml_i="88877" xml_f="89005" txt_i="14428" txt_f="14556">Overall, only 25 patients had converted to SPMS (5.9%, KM estimate) by year 11 (early 4.5%, delayed 8.3%, KM estimate; log rank </offsets><italic><offsets xml_i="89013" xml_f="89014" txt_i="14556" txt_f="14557">p</offsets></italic><offsets xml_i="89023" xml_f="89294" txt_i="14557" txt_f="14828"> = 0.4857). EDSS scores also did not differ between the treatment arms. EDSS scores of study participants remained low and stable with a median (quartile [Q]1, Q3) score of 2.0 (1.0, 3.0) and median change from baseline over 11 years of 0.5 (−0.50, 1.50) in both groups (</offsets><xref ref-type="table" rid="T2"><offsets xml_i="89326" xml_f="89333" txt_i="14828" txt_f="14835">table 2</offsets></xref><offsets xml_i="89340" xml_f="89454" txt_i="14835" txt_f="14946">). By year 11, 69.8% of patients were fully ambulatory with minor or no signs of disability (EDSS score &lt;3.0) (</offsets><xref ref-type="fig" rid="F2"><offsets xml_i="89484" xml_f="89493" txt_i="14946" txt_f="14955">figure 2C</offsets></xref><offsets xml_i="89500" xml_f="89502" txt_i="14955" txt_f="14957">).</offsets></p><table-wrap id="T2" orientation="portrait" position="float"><label><offsets xml_i="89573" xml_f="89580" txt_i="14958" txt_f="14965">Table 2</offsets></label><caption><p><offsets xml_i="89600" xml_f="89659" txt_i="14965" txt_f="15024">EDSS and employment at year 11 in the BENEFIT 11 population</offsets></p></caption><graphic xlink:href="NEUROLOGY2015695569TT2"></graphic></table-wrap><p><offsets xml_i="89744" xml_f="89967" txt_i="15025" txt_f="15248">As a neuropsychological measure, 222 patients had PASAT-3 data available at baseline and year 11. Over the entire study period, the PASAT-3 total score (adjusted for baseline score) was higher in the early-treatment group (</offsets><italic><offsets xml_i="89975" xml_f="89976" txt_i="15248" txt_f="15249">p</offsets></italic><offsets xml_i="89985" xml_f="89997" txt_i="15249" txt_f="15261"> = 0.0070) (</offsets><xref ref-type="fig" rid="F3"><offsets xml_i="90027" xml_f="90035" txt_i="15261" txt_f="15269">figure 3</offsets></xref><offsets xml_i="90042" xml_f="90632" txt_i="15269" txt_f="15856">). Two hundred thirty-three patients completed the SDMT (early 141, delayed 92). Overall median (Q1, Q3) SDMT score was 53.0 (44.0, 59.0), with little difference between groups. No differences were found between groups on the EQ-5D, FAMS trial outcomes index, Fatigue Scale for Motor and Cognitive Functions, or Center for Epidemiologic Studies Depression Scale with stable values relative to baseline for EQ-5D and FAMS, both of which had also been assessed at baseline. Absence of fatigue (score &lt;43) was reported in 128 patients (46%), and 191 (68.7%) reported no depressive symptoms.</offsets></p><fig id="F3" orientation="portrait" position="float"><label><offsets xml_i="90696" xml_f="90704" txt_i="15857" txt_f="15865">Figure 3</offsets></label><caption><title><offsets xml_i="90728" xml_f="90777" txt_i="15865" txt_f="15914">Mean PASAT-3 total score from baseline to year 11</offsets></title><p><offsets xml_i="90788" xml_f="90906" txt_i="15915" txt_f="16033">Over the entire study period, the mean PASAT-3 total score was higher in the early- than the delayed-treatment group (</offsets><italic><offsets xml_i="90914" xml_f="90915" txt_i="16033" txt_f="16034">p</offsets></italic><offsets xml_i="90924" xml_f="90984" txt_i="16034" txt_f="16094"> = 0.0070). PASAT-3 = Paced Auditory Serial Addition Task–3.</offsets></p></caption><graphic xlink:href="NEUROLOGY2015695569FF3"></graphic></fig><p><offsets xml_i="91062" xml_f="91108" txt_i="16095" txt_f="16141">Both groups had similar resource utilization (</offsets><xref ref-type="table" rid="T2"><offsets xml_i="91140" xml_f="91147" txt_i="16141" txt_f="16148">table 2</offsets></xref><offsets xml_i="91154" xml_f="91822" txt_i="16148" txt_f="16816">). Overall, 204 patients (73.4% of all patients in the 11-year follow-up) were still employed, compared with 226 patients (81.3%) at study start. Twenty-six patients (9.4%) were retired at year 11 (22 [7.9%] retired early). Two hundred seventy-one patients (97.5%) were living alone or with a spouse/partner/family, with only 3 (1.1%) living in a long-term care facility. Two hundred fifty-four patients (91.4%) had not been hospitalized because of MS in the 12 months before the 11-year assessment. Sixty-seven patients had used second-line therapy (14.3%, KM estimate: 21.2%) by year 11 (early 38 [13.0%, KM estimate: 19.1%], delayed 29 [16.5%, KM estimate: 24.4%]).</offsets></p></sec><sec id="s2-3"><title><offsets xml_i="91854" xml_f="91867" txt_i="16818" txt_f="16831">MRI outcomes.</offsets></title><p><offsets xml_i="91878" xml_f="92128" txt_i="16832" txt_f="17082">One hundred ninety-one patients had MRI scans (early 114, delayed 77). All MRI data are reported as median (Q1, Q3). Relatively little difference in cerebral lesion number or volume was seen between the 2 treatment groups. Brain volume was 1,527.0 cm</offsets><sup><offsets xml_i="92133" xml_f="92134" txt_i="17082" txt_f="17083">3</offsets></sup><offsets xml_i="92140" xml_f="92203" txt_i="17083" txt_f="17146"> (1,444.0, 1,595.0) in the early-treatment group and 1,514.0 cm</offsets><sup><offsets xml_i="92208" xml_f="92209" txt_i="17146" txt_f="17147">3</offsets></sup><offsets xml_i="92215" xml_f="92617" txt_i="17147" txt_f="17549"> (1,429.0, 1,575.5) in the delayed-treatment group. Ten patients (5.2%) had 1 Gd+ lesion (early 7 [6.1%], delayed 3 [3.9%]) and 6 patients (3.1%) had 2 to 5 Gd+ lesions (early 5 [4.4%], delayed 1 [1.3%]). The number of new T2 lesions since the patient's last study scan was 2.0 (0.0, 6.0) in the early-treatment arm and 2.0 (0.0, 6.5) in the delayed-treatment arm, while T2 lesion volume was 2,237.0 mm</offsets><sup><offsets xml_i="92622" xml_f="92623" txt_i="17549" txt_f="17550">3</offsets></sup><offsets xml_i="92629" xml_f="92661" txt_i="17550" txt_f="17582"> (618.0, 5,473.0) and 1,640.5 mm</offsets><sup><offsets xml_i="92666" xml_f="92667" txt_i="17582" txt_f="17583">3</offsets></sup><offsets xml_i="92673" xml_f="92705" txt_i="17583" txt_f="17615"> (911.0, 3,419.0), respectively.</offsets></p><p><offsets xml_i="92712" xml_f="92977" txt_i="17616" txt_f="17881">T1 hypointense lesion count was 4.0 (1.0, 11.0) in the early-treatment group and 2.0 (1.0, 6.0) in the delayed-treatment group. A regression model identified an effect of baseline T2 lesion count on the number of T1 lesions at year 11 (RR 1.02 [95% CI 1.02, 1.03], </offsets><italic><offsets xml_i="92985" xml_f="92986" txt_i="17881" txt_f="17882">p</offsets></italic><offsets xml_i="92995" xml_f="93093" txt_i="17882" txt_f="17977"> &lt; 0.0001), but treatment did not decrease the number of lesions (RR 1.29 [95% CI 0.95, 1.76], </offsets><italic><offsets xml_i="93101" xml_f="93102" txt_i="17977" txt_f="17978">p</offsets></italic><offsets xml_i="93111" xml_f="93122" txt_i="17978" txt_f="17989"> = 0.1030).</offsets></p></sec><sec id="s2-4"><title><offsets xml_i="93154" xml_f="93161" txt_i="17991" txt_f="17998">Safety.</offsets></title><p><offsets xml_i="93172" xml_f="93396" txt_i="17999" txt_f="18223">The frequency and type of adverse events reported were consistent with the known profile of interferon beta-1b. There were no new safety signals detected at year 11. No serious adverse events were reported during BENEFIT 11.</offsets></p></sec></sec><sec sec-type="discussion" id="s3"><title><offsets xml_i="93454" xml_f="93464" txt_i="18226" txt_f="18236">DISCUSSION</offsets></title><p><offsets xml_i="93475" xml_f="94713" txt_i="18237" txt_f="19475">Performing a comprehensive reassessment after 11 years in a well-characterized group of patients, systematically followed since the initial clinical manifestation, provides a unique opportunity to better understand the benefits of early treatment on outcomes relevant to patients and physicians. This long-term follow-up study provided Class IV evidence that time to CDMS was prolonged and that additional clinical measures (ARR, PASAT score) were improved by early treatment while both groups showed a generally mild disease course. If we consider the length of follow-up, this trial included a sizable proportion (71%) of the originally randomized patients from the centers participating in BENEFIT 11. The comparison of baseline and available follow-up characteristics of patients who did not participate with those who participated in BENEFIT 11 did not reveal sources of systematic bias by selective dropout. A factor that may be critical to interpretation of these data is the unblinding of the initial randomization that occurred after completion of the year 5 assessments and the uncontrolled nature of treatment after the placebo-controlled phase, a characteristic shared with natural history and observational treatment studies.</offsets></p><p><offsets xml_i="94720" xml_f="95264" txt_i="19476" txt_f="20017">Even if we consider this and differences in methodology that make cross-study comparisons difficult, several clinically relevant outcomes in the current study remained relatively stable over 11 years and compare favorably with those reported in natural history cohorts. This is reflected in the high proportion of patients having EDSS score &lt;3.0 and remaining employed through year 11 and in the low rate of conversion to SPMS. A natural history study from Canada found that after 10.2 years, 50% of the patients had reached EDSS score ≥3.0.</offsets><sup><xref rid="R24" ref-type="bibr"><offsets xml_i="95301" xml_f="95303" txt_i="20017" txt_f="20019">24</offsets></xref></sup><offsets xml_i="95316" xml_f="95669" txt_i="20019" txt_f="20372"> A group of 1,261 patients from 5 European countries with similar disease duration and demographics had rates of employment ranging from 51% to 63%, with the exception of patients from Italy where 78% remained employed (but in a population that on average was 3 years younger and had a 3-year shorter duration of disease than the BENEFIT 11 population).</offsets><sup><xref rid="R25" ref-type="bibr"><offsets xml_i="95706" xml_f="95708" txt_i="20372" txt_f="20374">25</offsets></xref></sup><offsets xml_i="95721" xml_f="95808" txt_i="20374" txt_f="20461"> A cohort of 241 patients with MS from Canada also had lower rates of employment (54%).</offsets><sup><xref rid="R24" ref-type="bibr"><offsets xml_i="95845" xml_f="95847" txt_i="20461" txt_f="20463">24</offsets></xref></sup><offsets xml_i="95860" xml_f="95950" txt_i="20463" txt_f="20553"> Natural history studies have reported median times to progressive disease ranging from 15</offsets><sup><xref rid="R26" ref-type="bibr"><offsets xml_i="95987" xml_f="95989" txt_i="20553" txt_f="20555">26</offsets></xref></sup><offsets xml_i="96002" xml_f="96014" txt_i="20555" txt_f="20567"> to 19 years</offsets><sup><xref rid="R27" ref-type="bibr"><offsets xml_i="96051" xml_f="96053" txt_i="20567" txt_f="20569">27</offsets></xref><offsets xml_i="96060" xml_f="96061" txt_i="20569" txt_f="20570">,</offsets><xref rid="R28" ref-type="bibr"><offsets xml_i="96093" xml_f="96095" txt_i="20570" txt_f="20572">28</offsets></xref></sup><offsets xml_i="96108" xml_f="96135" txt_i="20572" txt_f="20599"> since the original attack.</offsets><sup><xref rid="R29" ref-type="bibr"><offsets xml_i="96172" xml_f="96174" txt_i="20599" txt_f="20601">29</offsets></xref><offsets xml_i="96181" xml_f="96182" txt_i="20601" txt_f="20602">,</offsets><xref rid="R30" ref-type="bibr"><offsets xml_i="96214" xml_f="96216" txt_i="20602" txt_f="20604">30</offsets></xref></sup></p><p><offsets xml_i="96236" xml_f="96362" txt_i="20605" txt_f="20731">The more favorable outcomes as compared to natural course studies may be overestimated because of differences in ascertainment</offsets><sup><xref rid="R26" ref-type="bibr"><offsets xml_i="96399" xml_f="96401" txt_i="20731" txt_f="20733">26</offsets></xref><offsets xml_i="96408" xml_f="96409" txt_i="20733" txt_f="20734">,</offsets><xref rid="R30" ref-type="bibr"><offsets xml_i="96441" xml_f="96443" txt_i="20734" txt_f="20736">30</offsets></xref></sup><offsets xml_i="96456" xml_f="96563" txt_i="20736" txt_f="20843"> and temporal shifts with more recent studies showing better outcomes irrespective of treatment allocation.</offsets><sup><xref rid="R31" ref-type="bibr"><offsets xml_i="96600" xml_f="96602" txt_i="20843" txt_f="20845">31</offsets></xref></sup><offsets xml_i="96615" xml_f="97016" txt_i="20845" txt_f="21246"> Nevertheless, after 11 years, we observed a relative stability with no apparent difference between the randomization arms. A possible explanation of this relative stability may be found in the fact that both arms can be considered to have received treatment relatively early in the course of the disease as even the delayed-treatment group started treatment within a maximum of 2 years following CIS.</offsets></p><p><offsets xml_i="97023" xml_f="97645" txt_i="21247" txt_f="21869">Despite the relatively short delay in treatment initiation in the placebo group, measures reflecting clinical disease activity such as time to CDMS, time to first relapse, and relapse rates, as well as scores on the PASAT, the only neuropsychological test applied from baseline to year 11, still suggest persistent long-term benefits of the earlier treatment. Although the overall lower ARR favoring the earlier-treatment group appears to be mainly driven by differences in the first year of the core study, it is intriguing to see that in the early-treatment group, ARR remained lower in all but 2 of the follow-up years—</offsets></p><p><offsets xml_i="97652" xml_f="97910" txt_i="21870" txt_f="22128">This study adds to the literature on the optimal treatment of patients with MS by supporting and expanding the data on treatment at the earliest clinical manifestation of the disease. Other studies have shown benefits of early treatment for patients with CIS</offsets><sup><xref rid="R10" ref-type="bibr"><offsets xml_i="97947" xml_f="97949" txt_i="22128" txt_f="22130">10</offsets></xref><offsets xml_i="97956" xml_f="97957" txt_i="22130" txt_f="22131">,</offsets><xref rid="R32" ref-type="bibr"><offsets xml_i="97989" xml_f="97991" txt_i="22131" txt_f="22133">32</offsets></xref><offsets xml_i="97998" xml_f="97999" txt_i="22133" txt_f="22134">,</offsets><xref rid="R33" ref-type="bibr"><offsets xml_i="98031" xml_f="98033" txt_i="22134" txt_f="22136">33</offsets></xref></sup><offsets xml_i="98046" xml_f="98691" txt_i="22136" txt_f="22781">; however, BENEFIT 11 includes longer follow-up with additional outcome measures that have not previously been described, including resource use, employment status, and patient-reported outcomes. Despite the inherent problems of a comparison with natural course studies, our results indicate that early treatment with interferon beta-1b had a long-lasting, even remote, beneficial effect on disease activity as well as cognitive outcomes, resource utilization, and employment rate. Taken together, the findings of BENEFIT 11 reinforce the importance of starting therapy with interferon beta-1b as soon as possible after the onset of MS symptoms.</offsets></p></sec><offsets xml_i="98701" xml_f="98702" txt_i="22783" txt_f="22784">
</offsets><sec sec-type="supplementary-material"><offsets xml_i="98741" xml_f="98742" txt_i="22784" txt_f="22785">
</offsets><title><offsets xml_i="98749" xml_f="98771" txt_i="22785" txt_f="22807">Supplementary Material</offsets></title><offsets xml_i="98779" xml_f="98780" txt_i="22808" txt_f="22809">
</offsets><supplementary-material id="PMC_1" content-type="local-data"><offsets xml_i="98841" xml_f="98842" txt_i="22809" txt_f="22810">
</offsets><caption><offsets xml_i="98851" xml_f="98852" txt_i="22810" txt_f="22811">
</offsets><title><offsets xml_i="98859" xml_f="98874" txt_i="22811" txt_f="22826">Data Supplement</offsets></title><offsets xml_i="98882" xml_f="98883" txt_i="22827" txt_f="22828">
</offsets></caption><offsets xml_i="98893" xml_f="98894" txt_i="22828" txt_f="22829">
</offsets><media mimetype="text" mime-subtype="html" xlink:href="supp_87_10_978__index.html"></media><offsets xml_i="98985" xml_f="98986" txt_i="22829" txt_f="22830">
</offsets><media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_WNL.0000000000003078_Figure_e-1_LK.pdf"></media><offsets xml_i="99129" xml_f="99130" txt_i="22830" txt_f="22831">
</offsets></supplementary-material><offsets xml_i="99155" xml_f="99156" txt_i="22831" txt_f="22832">
</offsets><supplementary-material id="PMC_2" content-type="local-data"><offsets xml_i="99217" xml_f="99218" txt_i="22832" txt_f="22833">
</offsets><caption><offsets xml_i="99227" xml_f="99228" txt_i="22833" txt_f="22834">
</offsets><title><offsets xml_i="99235" xml_f="99250" txt_i="22834" txt_f="22849">Coinvestigators</offsets></title><offsets xml_i="99258" xml_f="99259" txt_i="22850" txt_f="22851">
</offsets></caption><offsets xml_i="99269" xml_f="99270" txt_i="22851" txt_f="22852">
</offsets><media mimetype="text" mime-subtype="html" xlink:href="supp_87_10_978_v2_index.html"></media><offsets xml_i="99363" xml_f="99364" txt_i="22852" txt_f="22853">
</offsets><media xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="supp_WNL.0000000000003078_Coinvestigator_appendix.docx"></media><offsets xml_i="99521" xml_f="99522" txt_i="22853" txt_f="22854">
</offsets></supplementary-material><offsets xml_i="99547" xml_f="99548" txt_i="22854" txt_f="22855">
</offsets><supplementary-material id="PMC_3" content-type="local-data"><offsets xml_i="99609" xml_f="99610" txt_i="22855" txt_f="22856">
</offsets><caption><offsets xml_i="99619" xml_f="99620" txt_i="22856" txt_f="22857">
</offsets><title><offsets xml_i="99627" xml_f="99649" txt_i="22857" txt_f="22879">Accompanying Editorial</offsets></title><offsets xml_i="99657" xml_f="99658" txt_i="22880" txt_f="22881">
</offsets></caption><offsets xml_i="99668" xml_f="99669" txt_i="22881" txt_f="22882">
</offsets><media mimetype="text" mime-subtype="html" xlink:href="supp_87_10_978_v3_index.html"></media><offsets xml_i="99762" xml_f="99763" txt_i="22882" txt_f="22883">
</offsets><media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_WNL.0000000000003078_970.pdf"></media><offsets xml_i="99896" xml_f="99897" txt_i="22883" txt_f="22884">
</offsets></supplementary-material><offsets xml_i="99922" xml_f="99923" txt_i="22884" txt_f="22885">
</offsets><supplementary-material id="PMC_4" content-type="local-data"><offsets xml_i="99984" xml_f="99985" txt_i="22885" txt_f="22886">
</offsets><caption><offsets xml_i="99994" xml_f="99995" txt_i="22886" txt_f="22887">
</offsets><title><offsets xml_i="100002" xml_f="100020" txt_i="22887" txt_f="22905">Short-Form Article</offsets></title><offsets xml_i="100028" xml_f="100029" txt_i="22906" txt_f="22907">
</offsets></caption><offsets xml_i="100039" xml_f="100040" txt_i="22907" txt_f="22908">
</offsets><media mimetype="text" mime-subtype="html" xlink:href="supp_87_10_978_v4_index.html"></media><offsets xml_i="100133" xml_f="100134" txt_i="22908" txt_f="22909">
</offsets><media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_WNL.0000000000003078_kappos.pdf"></media><offsets xml_i="100270" xml_f="100271" txt_i="22909" txt_f="22910">
</offsets></supplementary-material><offsets xml_i="100296" xml_f="100297" txt_i="22910" txt_f="22911">
</offsets></sec><offsets xml_i="100303" xml_f="100304" txt_i="22912" txt_f="22913">
</offsets></body><back><fn-group><fn fn-type="supplementary-material"><p>Supplemental data at <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000003078">Neurology.org</ext-link></p></fn><fn fn-type="other"><p>Editorial, page <related-article related-article-type="commentary" id="d36e4157" vol="87" page="970" issue="10" xlink:href="27511185" ext-link-type="pubmed">970</related-article></p></fn></fn-group><ack><title>ACKNOWLEDGMENT</title><p>The authors thank the patients and the BENEFIT 11 investigators for their continuing contributions to the study. Robert C. Ristuccia, PhD (Precept Medical Communications), provided writing assistance consisting of medical editing, English-language assistance, formatting of text and figures, and coordinating reviews, which was funded by Bayer HealthCare Pharmaceuticals. This article is dedicated to the memory of our colleague Christoph Pohl who passed away on August 28, 2015. His contributions to the BENEFIT Study have been invaluable and until his last days—although completely paralyzed by his progressive neuromuscular disease and on artificial respiration—he was actively involved in the development of this manuscript and accompanying scientific projects.</p></ack><sec sec-type="contributions"><title>AUTHOR CONTRIBUTIONS</title><p content-type="contributions">L. Kappos: planned the study, reviewed the statistical analysis, interpreted data, and actively contributed to the writing and reviewing of the submitted manuscript. Chair of the study steering committee and study investigator. G. Edan: interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the study steering committee and study investigator. M.S. Freedman: interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the study steering committee and study investigator. X. Montalbán: interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the study steering committee and study investigator. H.-P. Hartung: interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the study steering committee and study investigator. B. Hemmer: interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the study steering committee and study investigator. E. Fox: interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the study steering committee and study investigator. F. Barkhof: collected and analyzed the MRI data, reviewed the statistical analyses, and actively contributed to the writing and reviewing of the submitted manuscript. S. Schippling: interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the study steering committee and study investigator. A. Schulze: developed the statistical analysis plan, conducted the statistical analysis, interpreted data, and actively contributed to the writing and reviewing of the manuscript. D. Pleimes: drafted the statistical analysis plan, interpreted data, and drafted and reviewed the manuscript. C. Pohl: actively involved in drafting the MRI protocol and the statistical analysis plan, reviewed the statistical analyses, and actively contributed to the writing and reviewing of manuscript drafts. Sponsor's responsible clinician for the follow-up study phase. R. Sandbrink: interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the study steering committee. Sponsor's responsible clinician for the placebo-controlled study phase. G. Suarez: drafted the statistical analysis plan, interpreted data, and drafted and reviewed the manuscript. E.-M. Wicklein: drafted the statistical analysis plan, interpreted data, and drafted and reviewed the manuscript. Sponsor's responsible clinician for the extension study phase.</p></sec><sec sec-type="funding"><title>STUDY FUNDING</title><p content-type="funding">This study was funded by Bayer HealthCare Pharmaceuticals. Representatives of the study sponsor participated in the discussions of the steering committee on the design of the study, including the assessments to be made and the statistical analysis plan. They also provided input on the manuscript, with the understanding that the final decisions related to publication of these data would be made by the study steering committee.</p></sec><sec sec-type="disclosure"><title>DISCLOSURE</title><p content-type="disclosure">L. Kappos' institution (University Hospital Basel) has received in the last 3 years and used exclusively for research support: steering committee/consulting fees from Actelion, Addex, Bayer HealthCare, Biogen, Biotica, Genzyme, Lilly, Merck, Mitsubishi, Novartis, Ono, Pfizer, Receptos, Sanofi-Aventis, Santhera, Siemens, Teva, UCB, and Xenoport; speaker fees from Bayer HealthCare, Biogen, Merck, Novartis, Sanofi-Aventis, and Teva; support of educational activities from Bayer HealthCare, Biogen, CSL Behring, Genzyme, Merck, Novartis, Sanofi-Aventis, and Teva; royalties from Neurostatus Systems AG; grants from Bayer HealthCare, Biogen, the European Union, Merck, Novartis, Roche, Roche Research Foundations, the Swiss Multiple Sclerosis Society, and the Swiss National Research Foundation. G. Edan has received honoraria for lectures or consulting from Biogen Idec, Merck Serono, and Sanofi-Aventis, and received personal compensation for serving on the BENEFIT scientific advisory board and for speaking from Bayer Pharma AG. He has also received research support from Serono (a grant to University Hospital to support a research program on MRI in MS) and from Teva (a grant to support a research program on anti-IBF neutralizing antibodies). M. Freedman has received compensation from Bayer HealthCare, Biogen Idec, EMD Canada, Genzyme, Merck Serono, Novartis, Sanofi-Aventis, and Teva Canada Innovation for consulting services, and has received research/educational grants from Bayer HealthCare and Genzyme. He also participates in a Genzyme-sponsored speakers bureau. X. Montalbán has received speaking honoraria and travel expenses for scientific meetings and has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past years with Bayer, Biogen Idec, EMD, Genentech, Genzyme, Merck Serono, Neuro-Tec, Novartis, Sanofi-Aventis, Teva Pharmaceuticals, and Almirall. H. Hartung has received honoraria for consulting and speaking at symposia from Bayer Pharma AG, Biogen Idec, Genzyme, Merck Serono, Novartis, Roche, Teva, and Sanofi-Aventis, with approval by the rector of Heinrich-Heine University. B. Hemmer has served on scientific advisory boards for Roche, Novartis, Bayer Schering, Merck Serono, Biogen Idec, GSK, Chugai Pharmaceuticals, Micromet, and Genzyme Corporation; is author on patents re: KIR4.1 antibody testing in MS and genetic determinant of neutralizing antibody development in interferon-beta–treated patients; has received speaker honoraria from Bayer Schering, Novartis, Biogen Idec, Merck Serono, Roche, and Teva Pharmaceutical Industries Ltd.; and has received research support from Biogen Idec, Bayer Schering, Merck Serono, Five Prime, Metanomics, and Novartis. E. Fox has received consulting fees, honoraria, travel, or research support from Acorda, Bayer, Biogen Idec, Eli Lilly, EMD Serono, Genzyme, GlaxoSmithKline, Novartis, Ono, Opexa Therapeutics, Pfizer, Roche, Sanofi, and Teva. F. Barkhof has received compensation for consultancy from Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis, Genzyme, Roche, and Teva, and has received research support from the Dutch Foundation for MS Research (an NGO). S. Schippling has received research grants from Biogen Idec, Bayer Schering Pharma, and Genzyme, and consulting/speaker fees from Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, Teva, and Sanofi-Aventis. A. Schulze is a salaried employee of Bayer Pharma AG. At the time this work was conducted, she was a salaried employee of PAREXEL International. D. Pleimes is a salaried employee of Myelo Therapeutics GmbH. He was a salaried employee and is currently a paid consultant for Bayer HealthCare Pharmaceuticals. D.P. owns stock in Bayer AG, the owner of Bayer Pharma AG/Bayer HealthCare Pharmaceuticals. C. Pohl is deceased; disclosures are not included for this author. R. Sandbrink was a salaried employee of Bayer Pharma AG. He owns stock in Bayer AG, the owner of Bayer Pharma AG/Bayer HealthCare Pharmaceuticals. G. Suarez was a salaried employee of Bayer HealthCare Pharmaceuticals. E. Wicklein is salaried employee of Bayer Pharma AG. Go to <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000003078">Neurology.org</ext-link> for full disclosures.</p></sec><glossary><title>GLOSSARY</title><def-list><def-item><term id="G1">ARR</term><def><p>annualized relapse rate</p></def></def-item><def-item><term id="G2">BENEFIT</term><def><p>Betaferon/Betaseron in Newly Emerging MS for Initial Treatment</p></def></def-item><def-item><term id="G3">CDMS</term><def><p>clinically definite multiple sclerosis</p></def></def-item><def-item><term id="G4">CI</term><def><p>confidence interval</p></def></def-item><def-item><term id="G5">CIS</term><def><p>clinically isolated syndrome</p></def></def-item><def-item><term id="G6">DMT</term><def><p>disease-modifying therapy</p></def></def-item><def-item><term id="G7">EDSS</term><def><p>Expanded Disability Status Scale</p></def></def-item><def-item><term id="G8">EQ-5D</term><def><p>EuroQoL–5 Dimension</p></def></def-item><def-item><term id="G9">FAMS</term><def><p>Functional Assessment of Multiple Sclerosis</p></def></def-item><def-item><term id="G10">Gd+</term><def><p>gadolinium-enhancing</p></def></def-item><def-item><term id="G11">KM</term><def><p>Kaplan-Meier</p></def></def-item><def-item><term id="G12">MS</term><def><p>multiple sclerosis</p></def></def-item><def-item><term id="G13">PASAT</term><def><p>Paced Auditory Serial Addition Task</p></def></def-item><def-item><term id="G14">Q</term><def><p>quartile</p></def></def-item><def-item><term id="G15">RR</term><def><p>risk ratio</p></def></def-item><def-item><term id="G16">SDMT</term><def><p>Symbol Digit Modalities Test</p></def></def-item><def-item><term id="G17">SPMS</term><def><p>secondary progressive multiple sclerosis</p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Compston</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Coles</surname><given-names>A</given-names></name></person-group>
<article-title>Multiple sclerosis</article-title>. <source>Lancet</source>
<year>2008</year>;<volume>372</volume>:<fpage>1502</fpage>–<lpage>1517</lpage>.<pub-id pub-id-type="pmid">18970977</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>DH</given-names></name>, <name name-style="western"><surname>Chard</surname><given-names>DT</given-names></name>, <name name-style="western"><surname>Ciccarelli</surname><given-names>O</given-names></name></person-group>
<article-title>Clinically isolated syndromes</article-title>. <source>Lancet Neurol</source>
<year>2012</year>;<volume>11</volume>:<fpage>157</fpage>–<lpage>169</lpage>.<pub-id pub-id-type="pmid">22265211</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>DH</given-names></name>, <name name-style="western"><surname>Barkhof</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Montalban</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Thompson</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Filippi</surname><given-names>M</given-names></name></person-group>
<article-title>Clinically isolated syndromes suggestive of multiple sclerosis: part I: natural history, pathogenesis, diagnosis, and prognosis</article-title>. <source>Lancet Neurol</source>
<year>2005</year>;<volume>4</volume>:<fpage>281</fpage>–<lpage>288</lpage>.<pub-id pub-id-type="pmid">15847841</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Comi</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Filippi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Barkhof</surname><given-names>F</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study</article-title>. <source>Lancet</source>
<year>2001</year>;<volume>357</volume>:<fpage>1576</fpage>–<lpage>1582</lpage>.<pub-id pub-id-type="pmid">11377645</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Comi</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Martinelli</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Rodegher</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial</article-title>. <source>Lancet</source>
<year>2009</year>;<volume>374</volume>:<fpage>1503</fpage>–<lpage>1511</lpage>.<pub-id pub-id-type="pmid">19815268</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edan</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Kappos</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Montalban</surname><given-names>X</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT</article-title>. <source>J Neurol Neurosurg Psychiatry</source>
<year>2014</year>;<volume>85</volume>:<fpage>1183</fpage>–<lpage>1189</lpage>.<pub-id pub-id-type="pmid">24218527</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobs</surname><given-names>LD</given-names></name>, <name name-style="western"><surname>Beck</surname><given-names>RW</given-names></name>, <name name-style="western"><surname>Simon</surname><given-names>JH</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group</article-title>. <source>N Engl J Med</source>
<year>2000</year>;<volume>343</volume>:<fpage>898</fpage>–<lpage>904</lpage>.<pub-id pub-id-type="pmid">11006365</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kappos</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Polman</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Freedman</surname><given-names>MS</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes</article-title>. <source>Neurology</source>
<year>2006</year>;<volume>67</volume>:<fpage>1242</fpage>–<lpage>1249</lpage>.<pub-id pub-id-type="pmid">16914693</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kappos</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Freedman</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Polman</surname><given-names>CH</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT Study</article-title>. <source>Lancet</source>
<year>2007</year>;<volume>370</volume>:<fpage>389</fpage>–<lpage>397</lpage>.<pub-id pub-id-type="pmid">17679016</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kappos</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Freedman</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Polman</surname><given-names>CH</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial</article-title>. <source>Lancet Neurol</source>
<year>2009</year>;<volume>8</volume>:<fpage>987</fpage>–<lpage>997</lpage>.<pub-id pub-id-type="pmid">19748319</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kinkel</surname><given-names>RP</given-names></name>, <name name-style="western"><surname>Dontchev</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kollman</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Skaramagas</surname><given-names>TT</given-names></name>, <name name-style="western"><surname>O'Connor</surname><given-names>PW</given-names></name>, <name name-style="western"><surname>Simon</surname><given-names>JH</given-names></name></person-group>
<article-title>Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance</article-title>. <source>Arch Neurol</source>
<year>2012</year>;<volume>69</volume>:<fpage>183</fpage>–<lpage>190</lpage>.<pub-id pub-id-type="pmid">21987393</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurtzke</surname><given-names>JF</given-names></name></person-group>
<article-title>Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS)</article-title>. <source>Neurology</source>
<year>1983</year>;<volume>33</volume>:<fpage>1444</fpage>–<lpage>1452</lpage>.<pub-id pub-id-type="pmid">6685237</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischer</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Rudick</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Cutter</surname><given-names>GR</given-names></name>, <name name-style="western"><surname>Reingold</surname><given-names>SC</given-names></name></person-group>
<article-title>The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force</article-title>. <source>Mult Scler</source>
<year>1999</year>;<volume>5</volume>:<fpage>244</fpage>–<lpage>250</lpage>.<pub-id pub-id-type="pmid">10467383</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><collab>EuroQol Group</collab>. <article-title>EuroQol—a new facility for the measurement of health-related quality of life</article-title>. <source>Health Policy</source>
<year>1990</year>;<volume>16</volume>:<fpage>199</fpage>–<lpage>208</lpage>.<pub-id pub-id-type="pmid">10109801</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cella</surname><given-names>DF</given-names></name>, <name name-style="western"><surname>Dineen</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Arnason</surname><given-names>B</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Validation of the Functional Assessment of Multiple Sclerosis quality of life instrument</article-title>. <source>Neurology</source>
<year>1996</year>;<volume>47</volume>:<fpage>129</fpage>–<lpage>139</lpage>.<pub-id pub-id-type="pmid">8710066</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weissman</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Sholomskas</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Pottenger</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Prusoff</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Locke</surname><given-names>BZ</given-names></name></person-group>
<article-title>Assessing depressive symptoms in five psychiatric populations: a validation study</article-title>. <source>Am J Epidemiol</source>
<year>1977</year>;<volume>106</volume>:<fpage>203</fpage>–<lpage>214</lpage>.<pub-id pub-id-type="pmid">900119</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Penner</surname><given-names>IK</given-names></name>, <name name-style="western"><surname>Raselli</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Stocklin</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Opwis</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kappos</surname><given-names>L</given-names></name></person-group>
<article-title>The FSMC (Fatigue Scale for Motor and Cognitive Functions): a new patient-reported outcome measure for cognitive and motor fatigue in multiple sclerosis</article-title>. <source>Mult Scler</source>
<year>2006</year>;<volume>12</volume>(<issue>suppl 1</issue>):<fpage>S151</fpage>.</mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Penner</surname><given-names>IK</given-names></name>, <name name-style="western"><surname>Raselli</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Stocklin</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Opwis</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kappos</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Calabrese</surname><given-names>P</given-names></name></person-group>
<article-title>The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue</article-title>. <source>Mult Scler</source>
<year>2009</year>;<volume>15</volume>:<fpage>1509</fpage>–<lpage>1517</lpage>.<pub-id pub-id-type="pmid">19995840</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parmenter</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Weinstock-Guttman</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Garg</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Munschauer</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Benedict</surname><given-names>RH</given-names></name></person-group>
<article-title>Screening for cognitive impairment in multiple sclerosis using the Symbol Digit Modalities Test</article-title>. <source>Mult Scler</source>
<year>2007</year>;<volume>13</volume>:<fpage>52</fpage>–<lpage>57</lpage>.<pub-id pub-id-type="pmid">17294611</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>A</given-names></name></person-group>
<source>Symbol Digit Modalities Test (SDMT) Manual (Revised)</source>. <publisher-loc>Los Angeles</publisher-loc>: <publisher-name>Western Psychological Services</publisher-name>; <year>1982</year>.</mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lechner-Scott</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kappos</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Hofman</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Can the Expanded Disability Status Scale be assessed by telephone?</article-title>
<source>Mult Scler</source>
<year>2003</year>;<volume>9</volume>:<fpage>154</fpage>–<lpage>159</lpage>.<pub-id pub-id-type="pmid">12708811</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collins</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Ivry</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Bowen</surname><given-names>JD</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A comparative analysis of Patient-Reported Expanded Disability Status Scale tools</article-title>. Mult Scler Epub 2015 Nov 12. pii: 1352458515616205.</mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poser</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Paty</surname><given-names>DW</given-names></name>, <name name-style="western"><surname>Scheinberg</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group>
<article-title>New diagnostic criteria for multiple sclerosis: guidelines for research protocols</article-title>. <source>Ann Neurol</source>
<year>1983</year>;<volume>13</volume>:<fpage>227</fpage>–<lpage>231</lpage>.<pub-id pub-id-type="pmid">6847134</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karampampa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Gustavsson</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Miltenburger</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Kindundu</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Selchen</surname><given-names>DH</given-names></name></person-group>
<article-title>Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada</article-title>. <source>J Popul Ther Clin Pharmacol</source>
<year>2012</year>;<volume>19</volume>:<fpage>e11</fpage>–<lpage>e25</lpage>.<pub-id pub-id-type="pmid">22247419</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karampampa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Gustavsson</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Miltenburger</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Eckert</surname><given-names>B</given-names></name></person-group>
<article-title>Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries</article-title>. <source>Mult Scler</source>
<year>2012</year>;<volume>18</volume>(<issue>2 suppl</issue>):<fpage>7</fpage><lpage>15</lpage>.<pub-id pub-id-type="pmid">22623122</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scalfari</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Neuhaus</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Daumer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Muraro</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Ebers</surname><given-names>GC</given-names></name></person-group>
<article-title>Onset of secondary progressive phase and long-term evolution of multiple sclerosis</article-title>. <source>J Neurol Neurosurg Psychiatry</source>
<year>2014</year>;<volume>85</volume>:<fpage>67</fpage>–<lpage>75</lpage>.<pub-id pub-id-type="pmid">23486991</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eriksson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Andersen</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Runmarker</surname><given-names>B</given-names></name></person-group>
<article-title>Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis</article-title>. <source>Mult Scler</source>
<year>2003</year>;<volume>9</volume>:<fpage>260</fpage>–<lpage>274</lpage>.<pub-id pub-id-type="pmid">12814173</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tremlett</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Yinshan</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Devonshire</surname><given-names>V</given-names></name></person-group>
<article-title>Natural history of secondary-progressive multiple sclerosis</article-title>. <source>Mult Scler</source>
<year>2008</year>;<volume>14</volume>:<fpage>314</fpage>–<lpage>324</lpage>.<pub-id pub-id-type="pmid">18208898</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rovaris</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Confavreux</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Furlan</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Kappos</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Comi</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Filippi</surname><given-names>M</given-names></name></person-group>
<article-title>Secondary progressive multiple sclerosis: current knowledge and future challenges</article-title>. <source>Lancet Neurol</source>
<year>2006</year>;<volume>5</volume>:<fpage>343</fpage>–<lpage>354</lpage>.<pub-id pub-id-type="pmid">16545751</pub-id></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tremlett</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Rieckmann</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Hutchinson</surname><given-names>M</given-names></name></person-group>
<article-title>New perspectives in the natural history of multiple sclerosis</article-title>. <source>Neurology</source>
<year>2010</year>;<volume>74</volume>:<fpage>2004</fpage>–<lpage>2015</lpage>.<pub-id pub-id-type="pmid">20548045</pub-id></mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steinvorth</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Rover</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Schneider</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Nicholas</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Straube</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Friede</surname><given-names>T</given-names></name></person-group>
<article-title>Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression</article-title>. <source>Mult Scler</source>
<year>2013</year>;<volume>19</volume>:<fpage>1580</fpage>–<lpage>1586</lpage>.<pub-id pub-id-type="pmid">23471144</pub-id></mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Comi</surname><given-names>G</given-names></name>, <name name-style="western"><surname>De</surname><given-names>SN</given-names></name>, <name name-style="western"><surname>Freedman</surname><given-names>MS</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial</article-title>. <source>Lancet Neurol</source>
<year>2012</year>;<volume>11</volume>:<fpage>33</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="pmid">22146409</pub-id></mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Comi</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Martinelli</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Rodegher</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome</article-title>. <source>Mult Scler</source>
<year>2013</year>;<volume>19</volume>:<fpage>1074</fpage>–<lpage>1083</lpage>.<pub-id pub-id-type="pmid">23234810</pub-id></mixed-citation></ref></ref-list></back></article>